First global data, from Rosetta Lung-02 in first-line NSCLC, tell a familiar story.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
Lynparza/Imfinzi won’t progress in ovarian cancer, and another ceralasertib study fails.
The company will start a phase 2/3 trial of PF-08634404 in March.
New pivotal trials will soon start for LaNova’s ADC and FutureGen’s MAb.
The company’s latest phase 3 for its biparatopic ADC is in colorectal cancer.
Cogent joins OnKure with a clinical-stage H1047Rm-specific PI3Kα inhibitor.
After a phase 3 push the livmoniplimab plan falters.
